Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsHarvard Pilgrim Akynzeo Prior Auth Coverage | Open…
    Ask Trek AI about this page
    Currentharvard pilgrim health carePolicy N/A

    Akynzeo (netupitant/palonosetron) prior authorization

    Customize your policy alerts

    Sign up for all harvard pilgrim health care policy alerts

    Know when harvard pilgrim health care releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Prior authorization criteria for coverage of Akynzeo (netupitant/palonosetron) for prevention of chemotherapy-induced nausea and vomiting in adult members of Harvard Pilgrim and Tufts commercial products.

    Policy Summary
    Payerharvard pilgrim health care
    PolicyAkynzeo (netupitant/palonosetron) prior authorization
    Policy CodePolicy N/A
    Change TypeAdministrative clarifications
    Effective DateAug 11, 2026
    Last ReviewAug 13, 2024
    Next Review DateN/A
    Key ActionSubmit prior authorization with documentation showing patient is ≥18, receiving moderately to highly emetogenic IV chemotherapy per NCCN, and Akynzeo will be taken with dexamethasone.
    SourceLink
    POLICY UPDATE CHANGES

    Administrative update to add limitation statement for non-formulary medication request.

    Administrative update to remove Carelink from Medical Necessity Guideline template.

    Adult (≥18)age requirement
    Moderately–highly emetogenic IV chemoindication
    With dexamethasoneconcomitant med

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Harvard Pilgrim & Tufts
    applicable products
    NCCN Antiemesis v2.2026guideline

    Coverage Criteria for Akynzeo (netupitant/palonosetron)

    Clinical Guideline Coverage Criteria

    Covered when ALL of the following are met

    Main authorization criteria: Akynzeo is requested for the prevention of nausea and vomiting associated with cancer chemotherapy.

    Based on FDA indication and NCCN guidance

    Main authorization criteria: Patient is 18 years of age or older.

    Adults only per FDA-approved indication

    Main authorization criteria: Patient is receiving moderately to highly emetogenic intravenous chemotherapy as defined by the NCCN Clinical Practice Guidelines for Antiemesis.

    Refer to NCCN for emetogenicity classification

    Main authorization criteria: Akynzeo will be taken in combination with dexamethasone.

    Per FDA-approved indication — Akynzeo indicated with dexamethasone

    For requests involving a medication that is not on the plan formulary, the provider must follow the plan’s formulary exception process. Submit a formulary exception request to the plan per the Pharmacy Medical Necessity Guidelines for Formulary Exceptions so the non-formulary Akynzeo request can be reviewed for coverage.

    Initial Therapy

    Initial Therapy

    Initial coverage criteria

    Initial therapy criteria: Akynzeo is used with dexamethasone for adult patients (>=18 years) receiving moderately to highly emetogenic intravenous chemotherapy for prevention of acute and delayed chemotherapy-associated nausea and vomiting.

    Aligns with FDA-approved indication and NCCN guidance

    Provider Actions and Prior Authorization Requirements

    Prior Authorization

    Prior authorization required

    Prior authorization is required for Akynzeo; authorization may be granted when all clinical criteria are met for prevention of nausea and vomiting associated with cancer chemotherapy.

    Step Therapy

    No step therapy required

    No step therapy requirements are specified in this guideline.

    Documentation Required

    Required clinical documentation

    Documentation should support that Akynzeo is prescribed for prevention of acute and delayed nausea and vomiting associated with initial or repeat courses of cancer chemotherapy, that the patient is 18 years of age or older, that the chemotherapy is moderately to highly emetogenic per NCCN, and that Akynzeo will be taken with dexamethasone.

    Coding

    None listedmixed
    No codes listed

    Definitions

    Moderately to highly emetogenic chemotherapy (NCCN definition)
    Definition sourceAs defined by the NCCN Clinical Practice Guidelines in Oncology, Antiemesis (v2.2026)
    Emetogenicity categoryModerately to highly emetogenic chemotherapy
    Clinical contextUsed to describe IV chemotherapy regimens that carry moderate to high risk of causing acute and/or delayed nausea and vomiting per NCCN guidance
    Relevant guidelineNCCN Antiemesis v2.2026 referenced in policy References
    Associated therapyPolicy requires Akynzeo be used with dexamethasone for prevention of chemotherapy-associated nausea and vomiting in these regimens

    Background

    Akynzeo is an oral fixed combination of netupitant (an NK1 receptor antagonist) and palonosetron (a 5‑HT3 receptor antagonist) indicated, in combination with dexamethasone, for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of cancer chemotherapy, including moderately to highly emetogenic regimens. Palonosetron primarily prevents acute-phase events while netupitant contributes to prevention of both acute and delayed-phase events, aligning with guideline-recommended antiemesis strategies.

    Policy Summary
    Payerharvard pilgrim health care
    PolicyAkynzeo (netupitant/palonosetron) prior authorization
    Policy CodePolicy N/A
    Change TypeAdministrative clarifications
    Effective DateAug 11, 2026
    Last ReviewAug 13, 2024
    Next Review DateN/A
    Key ActionSubmit prior authorization with documentation showing patient is ≥18, receiving moderately to highly emetogenic IV chemotherapy per NCCN, and Akynzeo will be taken with dexamethasone.
    SourceLink
    On This Page
    Coverage Criteria for Akynzeo (netupitant/palonosetron)Initial TherapyProvider Actions and Prior Authorization RequirementsCodingDefinitionsBackground
    Denial Risk

    Denial triggers for incomplete criteria

    Requests that do not meet all clinical criteria may be denied.

    • Not prescribed for prevention of chemotherapy-associated nausea and vomiting
    • Patient under 18 years of age
    • Chemotherapy is not moderately to highly emetogenic per NCCN
    • Akynzeo not being taken with dexamethasone